Drugs & Targets FDA, industry actions end sales of PFAS in U.S. food packaging March 01, 2024Vol.50 No.09
Drugs & Targets FDA grants Epkinly priority review sBLA for difficult-to-treat R/R follicular lymphoma March 01, 2024Vol.50 No.09
Drugs & Targets FDA accepts BLA for Tevimbra for 1L treatment of G/GEJ cancers March 01, 2024Vol.50 No.09
Drugs & Targets Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI March 01, 2024Vol.50 No.09
Drugs & Targets Exact Sciences launches Riskguard hereditary cancer test in the U.S. March 01, 2024Vol.50 No.09
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
